162364-72-9

Basic information

• Product Name: 7-Benzyloxy-4-chloro-6-methoxyquinazoline
• Synonyms: 7-BENZYLOXY-4-CHLORO-6-METHOXY-QUINAZOLINE;4-Chloro-6-methoxy-7-benzyloxyquinazoline;Quinazoline, 4-chloro-6-Methoxy-7-(phenylMethoxy)-;4-chloro-7-benzyloxy -6-Methoxyquinazoline;4-chloro-6-methoxy-7-(phenylmethoxy)quinazoline
• CAS NO: 162364-72-9
• Molecular Formula: C₁₆H₁₃ClN₂O₂
• Molecular Weight: 300.74
• EINECS: 1533716-785-6
• Mol File: 162364-72-9.mol
• Article Data: 35

Chemical Properties

• Boiling Point: 452.06 °C at 760 mmHg
• Flash Point: 227.198 °C
• Appearance: /
• Density: 1.304 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.72±0.30(Predicted)
• CAS DataBase Reference: 7-Benzyloxy-4-chloro-6-methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Benzyloxy-4-chloro-6-methoxyquinazoline(162364-72-9)
• EPA Substance Registry System: 7-Benzyloxy-4-chloro-6-methoxyquinazoline(162364-72-9)

Safety Data

• Hazardous Substances Data: 162364-72-9(Hazardous Substances Data)

Usage

Description

7-Benzyloxy-4-chloro-6-methoxyquinazoline is a chemical compound belonging to the quinazoline class of organic compounds. It is a derivative of quinazoline, a bicyclic heterocyclic compound with a benzene ring fused to a pyrimidine ring. 7-Benzyloxy-4-chloro-6-methoxyquinazoline features a chloro group at the 4th position, a methoxy group at the 6th position of the quinazoline ring, and a benzyloxy group attached to the 7th position. Its unique chemical structure and properties make it a valuable tool for researchers and scientists in various fields, particularly in the pharmaceutical industry for the development of new drugs and molecular probes for biological studies.

Uses

Used in Pharmaceutical Industry:
7-Benzyloxy-4-chloro-6-methoxyquinazoline is used as a chemical compound for the development of new drugs and molecular probes for biological studies. Its specific chemical structure and properties make it a valuable tool for researchers and scientists in the field of pharmaceuticals.
Used in Drug Development:
7-Benzyloxy-4-chloro-6-methoxyquinazoline is used as a potential candidate in drug development due to its unique chemical structure and properties. It can be utilized in the design and synthesis of new drugs targeting various diseases and conditions.
Used in Molecular Probes for Biological Studies:
7-Benzyloxy-4-chloro-6-methoxyquinazoline is used as a molecular probe in biological studies to investigate the interactions between biological molecules and drug candidates. Its specific chemical structure allows for targeted studies and the development of novel therapeutic approaches.

InChI:InChI=1/C16H13ClN2O2/c1-20-14-7-12-13(18-10-19-16(12)17)8-15(14)21-9-11-5-3-2-4-6-11/h2-8,10H,9H2,1H3

Upstream product

• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 100-44-7 benzyl chloride 
• 121-33-5 vanillin 
• 617-05-0 ethyl vanillate 
• 185033-64-1 ethyl 4-benzyloxy-3-methoxybenzoate 
• 179688-01-8 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 61032-42-6 methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 

Downstream Products

• 413599-60-7 N-7-benzyloxy-(4-cyano-2-fluorophenyl)-6-methoxy-4-quinazolinylamine 
• 688025-25-4 N-(7-benzyloxy-6-methoxyquinazolin-4-yl)benzene-1,3-diamine 
• 320366-84-5 7-benzyloxy-4-(4-bromo-2-fluorophenoxy)-6-methoxyquinazoline 
• 320367-02-0 4-amino-7-benzyloxy-6-methoxyquinazoline 
• 331792-39-3 N-(5-{[7-(benzyloxy)-6-methoxyquinazolin-4-yl]amino}pyrimidin-2-yl)-3-chloro-4-fluorobenzamide 
• 516526-37-7 4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline 
• 848415-65-6 7-(benzyloxy)-N-(3-chloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine hydrochloride 
• 768350-54-5 7-(benzyloxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine hydrochloride 
• 263400-83-5 4-chloro-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 
• 193001-80-8 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline 
• 932016-10-9 7-hydroxy-4-(4-bromo-2-fluoroanilino)-6-methoxyquinazoline hydrochloride 
• 418811-67-3 7-benzyloxy-4-(3-chloroindol-7-ylamino)-6-methoxyquinazoline 
• 849217-65-8 cyclopropane-1,1-dicarboxylic acid [4-(7-benzyloxy-6-methoxy-quinazolin-4-yloxy)-3-fluoro-phenyl]-amide-(4-fluoro-phenyl)-amide 
• 338992-37-3 7-benzyloxy-4-(4-bromo-2,6-difluoroanilino)-6-methoxyquinazoline 

Relevant articles and documents

Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing

Histone lysine-specific demethylase 1 (LSD1) is an important epigenetic modulator, and is implicated in malignant transformation and tumor pathogenesis in different ways. Therefore, the inhibition of LSD1 provides an attractive therapeutic target for cancer therapy. Based on drug repurposing strategy, we screened our in-house chemical library toward LSD1, and found that the EGFR inhibitor erlotinib, an FDA-approved drug for lung cancer, possessed low potency against LSD1 (IC50 = 35.80 μM). Herein, we report our further medicinal chemistry effort to obtain a highly water-soluble erlotinib analog 5k (>100 mg/mL) with significantly enhanced inhibitory activity against LSD1 (IC50 = 0.69 μM) as well as higher specificity. In MGC-803 cells, 5k suppressed the demethylation of LSD1, indicating its cellular activity against the enzyme. In addition, 5k had a remarkable capacity to inhibit colony formation, suppress migration and induce apoptosis of MGC803 cells. Furthermore, in MGC-803 xenograft mouse model, 5k treatment resulted in significant reduction in tumor size by 81.6% and 96.1% at dosages of 40 and 80 mg/kg/d, respectively. Our findings indicate that erlotinib-based analogs provide a novel structural set of LSD1 inhibitors with potential for further investigation, and may serve as novel candidates for the treatment of LSD1-overexpressing cancers.

Heterocyclic compound, preparation method and application thereof

The invention relates to a heterocyclic compound in the technical field of medicines. The compound is represented by a structural general formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, X, Y, Z, Cy1, Cy2, m, n and t have the meanings given in the specification; in addition, the invention also discloses an application of the compound and the pharmaceuticallyacceptable salt thereof in preparation of drugs for treating diseases caused by abnormal high expression of tyrosine kinase, especially application in preparation of drugs for treating and preventingcancers.

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

EGFR and VEGFR-2 are involved in pathological disorders and the progression of different kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears to be an attractive approach to cancer therapy. In this work, a series of 4-anilinoquinazoline derivatives containing substituted diaryl urea or glycine methyl ester moiety were designed and identified as EGFR and VEGFR-2 dual inhibitors. Compounds 19i, 19j and 19l exhibited the most potent inhibitory activities against EGFR (IC50?=?1?nM, 78?nM and 51?nM, respectively) and VEGFR-2 (IC50?=?79?nM, 14?nM and 14?nM, respectively), they showed good antiproliferative activities as well. Molecular docking established the interaction of 19i with the DFG-out conformation of VEGFR-2, suggesting that they might be type II kinase inhibitors.